Table of Contents Author Guidelines Submit a Manuscript
Advances in Preventive Medicine
Volume 2011, Article ID 846756, 17 pages
http://dx.doi.org/10.4061/2011/846756
Review Article

Conjugate Meningococcal Vaccines Development: GSK Biologicals Experience

1GlaxoSmithKline Biologicals, 2301 Renaissance Boulevard, King of Prussia, PA 19406, USA
2GlaxoSmithKline Biologicals, Avenue Fleming 20 (W23), 1300 Wavre, Belgium

Received 30 November 2010; Accepted 19 April 2011

Academic Editor: Jodie McVernon

Copyright © 2011 Jacqueline M. Miller et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Meningococcal diseases are serious threats to global health, and new vaccines specifically tailored to meet the age-related needs of various geographical areas are required. This paper focuses on the meningococcal conjugate vaccines developed by GSK Biologicals. Two combined conjugate vaccines were developed to help protect infants and young children in countries where the incidence of meningococcal serogroup C or serogroup C and Y disease is important: Hib-MenC-TT vaccine, which offers protection against Haemophilus influenzae type b and Neisseria meningitidis serogroup C diseases, is approved in several countries; and Hib-MenCY-TT vaccine, which adds N. meningitidis serogroup Y antigen, is currently in the final stages of development. Additionally, a tetravalent conjugate vaccine (MenACWY-TT) designed to help protect against four meningococcal serogroups is presently being evaluated for global use in all age groups. All of these vaccines were shown to be highly immunogenic and to have clinically acceptable safety profiles.